Charles River Laboratories International (NYSE:CRL) Announces Earnings Results

Charles River Laboratories International (NYSE:CRL - Get Free Report) announced its quarterly earnings data on Wednesday. The medical research company reported $2.66 EPS for the quarter, topping analysts' consensus estimates of $2.50 by $0.16, Zacks reports. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The company had revenue of $1 billion during the quarter, compared to the consensus estimate of $983.63 million. During the same quarter last year, the company earned $2.46 EPS. The company's quarterly revenue was down 1.1% on a year-over-year basis. Charles River Laboratories International updated its FY 2025 guidance to 9.100-9.600 EPS and its FY25 guidance to $9.10-$9.60 EPS.

Charles River Laboratories International Stock Up 0.5 %

Shares of CRL traded up $0.86 during midday trading on Friday, hitting $163.11. The stock had a trading volume of 1,211,286 shares, compared to its average volume of 1,047,886. The company has a 50 day simple moving average of $173.39 and a two-hundred day simple moving average of $188.81. Charles River Laboratories International has a twelve month low of $150.79 and a twelve month high of $275.00. The firm has a market cap of $8.34 billion, a price-to-earnings ratio of 1,087.39, a price-to-earnings-growth ratio of 6.77 and a beta of 1.37. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.41 and a quick ratio of 1.14.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on CRL shares. William Blair cut Charles River Laboratories International from an "outperform" rating to a "market perform" rating in a report on Wednesday, January 22nd. StockNews.com cut Charles River Laboratories International from a "buy" rating to a "hold" rating in a report on Thursday, November 7th. The Goldman Sachs Group lowered their target price on Charles River Laboratories International from $220.00 to $190.00 and set a "buy" rating for the company in a research note on Thursday, January 23rd. Morgan Stanley reduced their price target on Charles River Laboratories International from $220.00 to $184.00 and set an "equal weight" rating on the stock in a research report on Wednesday, February 5th. Finally, Evercore ISI raised their price target on Charles River Laboratories International from $190.00 to $225.00 and gave the stock an "in-line" rating in a research report on Thursday, November 7th. Three research analysts have rated the stock with a sell rating, thirteen have issued a hold rating and one has issued a buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Hold" and a consensus target price of $195.71.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).